title: The effects of mometasone furoate and desloratadine in obstructive sleep apnea syndrome patients with allergic rhinitis.
abstract: BACKGROUND
  Allergic rhinitis (AR) and obstructive sleep apnea syndrome (OSAS) are worldwide prevalent diseases. These diseases impair patient quality of life. The aim of this study was to investigate and compare the efficacy of treatment of AR on OSAS by objective and subjective methods.
  
  
  METHODS
  The study group was composed of 80 OSAS patients with AR between the ages of 30 and 50 years. The patients were admitted with the complaint of snoring, and they were asked about AR-related symptoms (nasal discharge, nasal itching, sneeze, and nasal obstruction). Daytime somnolence was measured by the Epworth sleepiness scale (ESS). Sleep parameters on polysomnography tests before and after treatment were compared, and the effects of different AR treatment protocols on sleep quality were evaluated.
  
  
  RESULTS
  When pretreatment and posttreatment apnea-hypopnea index (AHI) values of the groups were compared, the most significant difference was observed in the nasal steroid (Ns) + antihistamine (Ah) group (p < 0.05). The ESS results were significantly decreased in the Ns and Ns + Ah groups after treatment (p < 0.05). AHI oxygen saturation <90% were significantly decreased in the Ns and Ns + Ah groups after treatment (p < 0.05).
  
  
  CONCLUSIONS
  Nasal obstruction due to nasal congestion causes increases in airway resistance and can lead to development of OSAS. We concluded that treating AR with Ns has both positive effects on OSAS and daily activity. However, adding Ah to this treatment did not show improved effects compared with placebo treatment.
authors.affiliation: Ear, Nose, and Throat Department, Yunus Emre State Hospital, Eskisehir, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Acar
authors.forename: Cemal
authors.initials: C
authors.lastname: Cingi
authors.forename: Oner
authors.initials: O
authors.lastname: Sakallioglu
authors.forename: Turhan
authors.initials: T
authors.lastname: San
authors.forename: Mehmet
authors.initials: M
authors.lastname: Fatih Yimenicioglu
authors.forename: Cengiz
authors.initials: C
authors.lastname: Bal
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D006970:Disorders of Excessive Somnolence / Q000209:etiology; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000627:therapeutic use*; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D020181:Sleep Apnea, Obstructive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D039563:Histamine H1 Antagonists, Non-Sedating; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D017336:Loratadine; C121345:desloratadine